Focused On-demand Library for Small ribosomal subunit protein mS27

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q92552

UPID:

RT27_HUMAN

Alternative names:

28S ribosomal protein S27, mitochondrial; Mitochondrial ribosomal protein S27

Alternative UPACC:

Q92552; B4DRT2; Q6P1S1

Background:

Small ribosomal subunit protein mS27, also known as 28S ribosomal protein S27, mitochondrial, and Mitochondrial ribosomal protein S27, is a crucial RNA-binding component of the mitochondrial small ribosomal subunit (mt-SSU). It plays a pivotal role in mitochondrial protein synthesis, stimulating mitochondrial mRNA translation of subunit components of the mitochondrial electron transport chain. Furthermore, it binds to the mitochondrial 12S rRNA and tRNA(Glu), showcasing its multifaceted role in cellular function.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein mS27 could open doors to potential therapeutic strategies, especially considering its involvement in positive regulation of cell proliferation and tumor cell growth. This insight offers a promising avenue for the development of novel treatments targeting mitochondrial dysfunctions and cancer.